We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

139 hedge funds and large institutions have $1.17B invested in Avidity Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 78 increasing their positions, 25 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,483% more call options, than puts

Call options by funds: $2.85M | Put options by funds: $180K

212% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.55% less ownership

Funds ownership: 107.76% → 107.21% (-0.55%)

6% less funds holding

Funds holding: 148 → 139 (-9)

26% less capital invested

Capital invested by funds: $1.57B → $1.17B (-$404M)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

Holders
139
Holders Change
-9
Holders Change %
-6.08%
% of All Funds
2.22%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
78
Reduced
25
Closed
23
Calls
$2.85M
Puts
$180K
Net Calls
+$2.67M
Net Calls Change
+$5.08M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$21.2M
2
State Street
State Street
Massachusetts
+$17.8M
3
RI
RTW Investments
New York
+$17.2M
4
Artisan Partners
Artisan Partners
Wisconsin
+$13.3M
5
BBA
Baker Bros. Advisors
New York
+$12.5M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$44.2M
2
Millennium Management
Millennium Management
New York
-$16.7M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$10.2M
4
SCM
Soleus Capital Management
Connecticut
-$6.88M
5
DTC
Deep Track Capital
Connecticut
-$6.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$105M +$3.46M +157,098 +2%
RCM
2
RA Capital Management
Massachusetts
$98.5M +$21.2M +962,465 +18%
RI
3
RTW Investments
New York
$98M +$17.2M +781,612 +14%
BlackRock
4
BlackRock
New York
$86.5M +$7.64M +347,251 +7%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$83.2M +$10.9M +493,679 +10%
CAC
6
Cowen and Company
New York
$70.5M +$6.7M +304,600 +7%
State Street
7
State Street
Massachusetts
$67.2M +$17.8M +806,933 +23%
Vanguard Group
8
Vanguard Group
Pennsylvania
$53.4M +$244K +11,091 +0.3%
CAM
9
Cormorant Asset Management
Massachusetts
$40.1M -$3.3M -150,000 -5%
ACA
10
Avoro Capital Advisors
New York
$38.5M +$10.1M +460,000 +22%
Federated Hermes
11
Federated Hermes
Pennsylvania
$36.3M – – –
Artisan Partners
12
Artisan Partners
Wisconsin
$29.2M +$13.3M +604,345 +46%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$20M +$3.95M +179,655 +16%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$19.5M +$7.63M +346,686 +38%
APM
15
Avidity Partners Management
Texas
$19.4M -$44.2M -2,009,455 -61%
Morgan Stanley
16
Morgan Stanley
New York
$19.2M +$5.01M +227,610 +22%
BC
17
Boxer Capital
California
$17.2M – – –
Goldman Sachs
18
Goldman Sachs
New York
$15.6M -$2.32M -105,312 -9%
BBA
19
Baker Bros. Advisors
New York
$15.4M +$12.5M +569,269 +131%
CC
20
Casdin Capital
New York
$13M – – –
ACM
21
Alethea Capital Management
Washington
$13M +$532K +24,178 +3%
5VM
22
5AM Venture Management
California
$10.2M – – –
Balyasny Asset Management
23
Balyasny Asset Management
Illinois
$9.55M -$592K -26,912 -4%
Northern Trust
24
Northern Trust
Illinois
$9.23M +$1.62M +73,552 +14%
CC
25
Commodore Capital
New York
$9.07M – – –
1
2 3 4 5

RNAM Hedge Fund Activity: Q1 2023 in Review

139 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2023, worth a combined $1.17B — down 26% from $1.57B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of RNAM and 15 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 78 added.

The largest buyer was RA Capital Management, adding an estimated $21.2M. The largest seller was Avidity Partners Management, cutting an estimated $44.2M.

  • 139 institutional investors held Avidity Biosciences (RNAM) as of Q1 2023, down from 148 in Q4 2022.
  • Funds reported $1.17B of Avidity Biosciences stock for Q1 2023, down 26% quarter-over-quarter.
  • 15 funds opened new Avidity Biosciences positions in Q1 2023 and 23 closed out, a net change of -8 holders.
  • The largest Avidity Biosciences buyer in Q1 2023 was RA Capital Management, an estimated $21.2M added.
  • The largest Avidity Biosciences seller in Q1 2023 was Avidity Partners Management, an estimated $44.2M sold.

Based on aggregated 13F filings for Q1 2023.